Therapeutics News and Research

RSS

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

In a recent study published in the journal PNAS, researchers from Finland and the United States reported a novel heptad repeat 2 (HR2) peptide that inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without any chemical modifications.

21 Sep 2022

Public-private collaboration receives grant for research on microbiota-boosted cancer therapy

Health~Holland has awarded close to € 800,000 to a public-private partnership between UMC Utrecht, Artizan Biosciences, Inc. (USA) and MicroViable Therapeutics (Spain) to unravel how the intestinal microbiota can be exploited to boost cancer immunotherapy and limit therapy side-effects.

21 Sep 2022

Cell's anti-aging structures can set the damage threshold a cancer cell can sustain, study shows

A new study led by Claus M. Azzalin, group leader at Instituto de Medicina Molecular João Lobo Antunes- iMM and published today in the prestigious scientific journal Proceedings of the National Academy of Sciences (PNAS) shows, for the first time, that the cell's anti-aging structures – the telomeres – can set the damage threshold a cancer cell can sustain and above which cells cannot continue to divide and die.

20 Sep 2022

Endogenous exosomes act as decoys for SARS-CoV-2

A recent study published in the journal PLoS Biology discussed exosomes as potential decoys for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Sep 2022

New catheter leads to a remarkable reduction in pulmonary artery obstruction

A device known as the BASHIR™ Endovascular Catheter (THROMBOLEX, Inc.) significantly reduces the size of blood clots lodged in the pulmonary arteries, leading to improvement in heart function in patients with pulmonary embolism, researchers from the Lewis Katz School of Medicine at Temple University announced in a Late-Breaking Innovation session at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston.

19 Sep 2022

Intact autophagic vacuoles found to be indispensable in mediating competitive elimination of cancer cells

Elimination of transformed cells that can initiate cancer is necessary to maintain tissue integrity. In a new study, scientists from Tokyo University of Science show how this mechanism is regulated by the cellular process "autophagy."

19 Sep 2022

Study explores the long-term impact of telemedicine on child neurology care

Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children's Hospital of Philadelphia (CHOP) found that across nearly 50,000 visits, patients continued to use telemedicine effectively even with the reopening of outpatient clinics a year after the onset of the COVID-19 pandemic.

16 Sep 2022

Study identifies a promising target for polycystic kidney disease treatment

Blocking the inhibition of PKD1 and PKD2 gene expression by deleting a binding site for microRNAs hindered the formation and growth of kidney cysts in autosomal dominant polycystic kidney disease (ADPKD) models, UT Southwestern researchers reported.

16 Sep 2022

ValitaCell joins Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announces it has acquired ValitaCell Ltd., a biotechnology company that creates pioneering analytical products and technologies for the biopharmaceutical industry.

From Beckman Coulter Life Sciences 16 Sep 2022

Strains within gut microbial species codiversified with human populations, study finds

Strains within dozens of bacterial species in the gut microbiota codiversified with human populations as they spread across the globe, according to a new study. The findings underscore the importance of understanding the potential role of population-specific microbial strains in microbiome-mediated disease and microbiota-based therapeutics.

15 Sep 2022

Disruption of actin cytoskeleton is key to triggering human immune response, research finds

Researchers from Cleveland Clinic's Florida Research and Innovation Center (FRIC) found that disruption of a cellular structure, known as the actin cytoskeleton, is a "priming signal" for the body to respond to a virus.

15 Sep 2022

Understanding what happens when two gut microbiomes clash together

Fecal microbiota transplantation (FMT) – the transfer of lower intestinal fluids and microbes from one individual to another – is sometimes used to treat inflammatory gut diseases, including ulcerative colitis and bacterial infections.

15 Sep 2022

Gut microbiome associated with multiple sclerosis risk and disease development

An international research consortium led by UC San Francisco scientists has shown significant differences between the gut bacteria profiles of multiple sclerosis (MS) patients and healthy individuals, as well as between MS patients receiving different drug treatments.

15 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

COVID-19's future is uncertain as infections increase and tracking decreases

Researchers review how the SARS-CoV-2 genome has changed throughout the COVID-19 pandemic.

14 Sep 2022

New drug marks cancer cells for destruction by the immune system

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks.

13 Sep 2022

Study identifies mechanism behind 'cytokine storm' in COVID-19 patient lungs

A new study by HSS Research Institute scientists identifies a mechanism by which SARS-CoV-2 induces the inflammatory response in COVID-19 patient lungs, so-called "cytokine storm", that can lead to lasting tissue damage and poor patient outcomes.

13 Sep 2022

How effective is vitamin D supplementation in COVID-19?

The current paper addresses the considerable evidence now supporting the efficacy of vitamin D in COVID-19, as well as its safety.

13 Sep 2022

HSD3B1 gene holds clues for predicting and treating endometrial cancer

The HSD3B1 gene could hold clues for predicting and treating endometrial cancer, according to a novel finding from the Cleveland Clinic's Lerner Research Institute.

13 Sep 2022

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

13 Sep 2022